Your submission is now in Draft mode.

Once it's ready, please submit your draft for review by our team of Community Moderators. Thank you!

Submit Essay

Once you submit your essay, you can no longer edit it.


This content now needs to be approved by community moderators.


This essay was submitted and is waiting for review.

% S:N501 in U.S. for week of 1 March?


In the past two months, three distinct SARS-CoV-2 variants of concern have been detected and are now the subject of intense study: B.1.1.7, B.1.351, and P.1. B.1.1.7 is thought to have emerged in the UK in November 2020 and is likely significantly more transmissible than preexisting variants of SARS-CoV-2. B.1.351 was first detected in South Africa in October 2020 and seems to have an ability to escape the neutralizing antibody response elicited by previous infection and reduce the efficacy of vaccines in development. P.1 was first detected in Brazil in January 2020 and, like B.1.351, seems like it is able to escape the neutralizing antibody response elicited by previous infection. All three of these variants have a S:N501 mutation that differentiates them from other variants.

According to data from the recently launched, the three variants in question — B.1.1.7, B.1.351, P.1 — are steadily increasing as a proportion of overall sequenced SARS-CoV-2 cases in the US.

The proportion of S:N501 among all sequenced SARS-CoV-2 samples submitted to the GISAID database in the US for the week of 2021-01-11 (2021-01-11 to 2021-01-17, inclusive) was 0.05, or 5%. Note that data for previous weeks are backfilled with sequences uploaded at later dates, so these percentages might change slightly over time — in other words, there is a lag between sequence collection and sequence upload.

In response to an increased incidence of S:N501 variants, public health officials may promote mitigation measures, further focus on contact tracing, and increase the rate of genomic sequencing.

Data sources and more information:

What will be the percent of S:N501 sequences in the U.S. among all positive SARS-CoV-2 samples submitted to the GISAID database of genetic sequences between 2021-03-01 and 2021-03-07 (inclusive)?

This question will resolve as the percentage of US S:N501 sequences among all positive SARS-CoV-2 samples submitted for genomic sequencing to the GISAID database between 2021-03-01 and 2021-03-07 (inclusive), as displayed on the "Distribution of S:N501 per country" plot on following website: This website pulls data from GISAID and makes it publicly accessible. This percentage will be accessed no sooner than 2021-03-15.

Make a Prediction


Note: this question resolved before its original close time. All of your predictions came after the resolution, so you did not gain (or lose) any points for it.

Note: this question resolved before its original close time. You earned points up until the question resolution, but not afterwards.

Current points depend on your prediction, the community's prediction, and the result. Your total earned points are averaged over the lifetime of the question, so predict early to get as many points as possible! See the FAQ.